Suppression of maternal virus load with zidovudine, didanosine, and indinavir combination therapy prevents mother-to-fetus HIV transmission in macaques

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue 2, 2000, Pages 140-149

  Ho, Rodney J Y ^a   Larsen, Kay ^a   Bui, Tot ^a   Wang, Xiao Y ^a   Herz, Arnd M ^b   Sherbert, Cynthia ^a   Finn, Eric ^a   Nosbisch, Connie ^a   Schmidt, Ann ^a   Anderson, David ^a   Agy, Michael ^a   Morton, William R ^a   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

Anti HIV therapy; Combination therapy; Maternal fetal transmission

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; RITONAVIR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MACACA; MONONUCLEAR CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS CULTURE; VIRUS LOAD;

EID: 0034298215     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200010010-00008     Document Type: Article

References (47)

1. Current and future dimensions of the HIV/AIDS pandemic in women and children
2. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
3. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: Results of Pediatric AIDS Clinical Trials Group protocol 185
4. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial
5. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: A randomised trial
6. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial
7. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIV-NET 012 randomised trial
8. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission
9. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model
10. Quantitation of human immunodeficiency virus type 1 during pregnancy: Relationship of viral titer to mother-to-child transmission and stability of viral load
11. Maternal plasma human immunodeficiency virus type 1 RNA level: A determinant and projected threshold for mother-to-child transmission
12. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant
13. Development of a chronically catheterized maternal-fetal macaque model to study in utero mother-to-fetus HIV transmission: A preliminary report
14. Alternatives to chronic restraint of nonhuman primates
15. Plasma viremia in macaques infected with simian immunodeficiency virus: Plasma viral load early in infection predicts survival
16. Characterization of macaque placental trophoblast and Hofbauer-cell response to zidovudine
17. Inoculation of baboons and macaques with simian immunodeficiency virus/Mne, a primate lentivirus closely related to human immunodeficiency virus type 2
18. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations
19. Pharmacokinetics of zidovudine (azidothymidine). I. Transplacental transfer
20. Pharmacokinetics of dideoxyinosine in pigtailed macaques (Macaca nemestrina) after intravenous and subcutaneous administration
21. Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques
22. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor
23. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082)
24. Fetal, infant, and maternal toxicity of zidovudine (azidothymidine) administered throughout pregnancy in Macaca nemestrina
25. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine
26. Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant
27. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission
28. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
29. Guidelines for the use of antiretroviral agents in HIV-infected adults
30. Perinatal HIV-1 transmission: Recent advances and therapeutic interventions
31. Antiretroviral therapies in pregnancy: Maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study
32. Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women
33. IgG, IgM, and IgA response to HIV in infants born to HIV-1 infected mothers
34. Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers
35. CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children
36. Lymphocyte proliferative responses to HIV-1 envelope and core antigens by infected and uninfected adults and children
37. Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms
38. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease
39. Viral load and disease progression in infants infected with human immunodeficiency virus type 1
40. Early prognostic indicators in primary perinatal human immunodeficiency virus type 1 infection: Importance of viral RNA and the timing of transmission on long-term outcome
41. Early HIV-specific cytotoxic T lymphocytes and disease progression in children born to HIV-infected mothers
42. CD8+ T-cell-mediated suppression of HIV replication in the first year of life: Association with lower viral load and favorable early survival
43. Viral phenotype and host-cell susceptibility to HIV-1 infection as risk factors for mother-to-child HIV-1 transmission
44. Intra-amniotic inoculation of pigtailed macaque (Macaca nemestrina) fetuses with SIV and HIV-1
45. Maternal transmission of SIVsmm in rhesus macaques
46. Genotype analysis of infant macaques infected transplacentally and orally
47. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection